Scinai Immunotherapeutics (SCNI) Stock Statistics & Valuation Metrics

Scinai Immunotherapeutics has a market cap or net worth of $758.13K. The enterprise value is $7.79M.

Scinai Immunotherapeutics has 706,586 shares outstanding. The number of shares has decreased by -2.65% in one year.

Scinai Immunotherapeutics’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -72.73%.

The current PE Ratio of Scinai Immunotherapeutics is ―. Scinai Immunotherapeutics’s PEG ratio is 0.00124.

In the last 12 months, Scinai Immunotherapeutics had revenue of 1.31M and earned -8.31M in profits. Earnings per share was -36.00.

In the last 12 months, operating cash flow was -7.40M and capital expenditures -127.81K, giving a free cash flow of -7.53M billion.

Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Scinai Immunotherapeutics upcoming earnings date is Dec 2, 2026, TBA (Confirmed).

Scinai Immunotherapeutics as a current ratio of 1.30, with Debt / Equity ratio of 30.51%

In the past 12 months, Scinai Immunotherapeutics has paid 0.00 in taxes.

Scinai Immunotherapeutics EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.37.

Scinai Immunotherapeutics has $2.85M in cash and marketable securities with $3.58M in debt, giving a net cash position of -$726.99K billion.

Gross margin is -252.45%, with operating margin of -575.29%, and net profit margin of -633.64%.

The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―